Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Perjeta Approved for Certain Type of Early BC

Genentech news release; 2017 Dec 20

The FDA has approved Perjeta (pertuzumab), in combination with Herceptin (trastuzumab) and chemotherapy for adjuvant treatment for a certain type of early breast cancer.

Indications: Perjeta is a HER2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence.

Dosage and administration: Administer by intravenous infusion postoperatively every 3 weeks for a total of 1 year (up to 18 cycles).

Efficacy and safety: Approval is based on results of a phase 3 study showing that the combination significantly reduced the risk of invasive breast cancer recurrence or death by 18% vs trastuzumab and chemotherapy alone.

Side effects/risks: The most common adverse reactions are diarrhea, nausea, alopecia, fatigue, peripheral neuropathy, and vomiting.


FDA Approves Genentech’s Perjeta (pertuzumab) for Adjuvant Treatment of Specific Type of Early Breast Cancer [news release]. South San Francisco, CA: Genentech, Inc. December 20, 2017. Accessed December 31, 2017.

Perjeta [package insert]. South San Francisco, CA: Genentech, Inc., 2017. Accessed December 31, 2017.

This Week's Must Reads

Haplo-HCT shows viability in DLBCL, Dreger P et al. Blood Adv. 2019 Feb 12;3(3):360-9

First-line avelumab/axitinib for RCC benefits wide range of patients, Choueiri TK et al. GUCS 2019, Abstract 544.

Inadequate emergency care a challenge for rural pediatric patients, Walling EB et al. J Oncol Pract. 2019 Jan 31. doi: 10.1200/JOP.18.00115.

QC measures improve with CMS Oncology Care Model, Rocque G et al. J Oncol Pract. 2019. doi: 10. 1200/JOP.18.00390.

Women less likely to receive industry funds, Weng JK et al. JAMA Netw Open. 2019 Jan. 25. doi: 10.1001/jamanetworkopen.2018.7377.

Must Reads in Breast Cancer

Therapeutic drug monitoring for tamoxifen not justified, Sanchez-Spitman A et al. J Clin Oncol. 2019 Jan 24. doi: 10.1200/JCO.18.00307.

With a positive sentinel node, RT better than surgery, Rutgers EJT et al. SABCS 2018, Abstract GS4-01

Ten years of anastrozole boosts disease-free survival, Ohtani S et al. SABCS 2018, Abstract GS3-04

Advanced age not linked with risk from nipple-sparing mastectomy, Cox S et al. and Bartholomew AJ et al. Session SF310 ACS Clinical Congress 2018